Consistent with observations from the large, two-cohort, phase 2 trial, a phase 2b study evaluating the effects of quizartinib at lower doses (starting doses of 30 or 60 mg/day) in a similar patient population (i.e., relapsed/refractory FLT3-ITD-mutated AML; N = 76) showed strong single-agent clinical activity, with an overall CRc of 47% [28]. Here, FLT3 is linked to acute myeloid leukemia.